Literature DB >> 29741779

N1-methylnicotinamide (MNAM) as a guardian of cardiovascular system.

Hamid Reza Nejabati1,2, Aynaz Mihanfar1, Masoud Pezeshkian3, Amir Fattahi1, Zeinab Latifi1,2, Naser Safaie3, Mohammad Valiloo2, Ahmad Reza Jodati3, Mohammad Nouri1.   

Abstract

Atherosclerosis is identified as the formation of atherosclerotic plaques, which could initiate the formation of a blood clot in which its growth to coronary artery can lead to a heart attack. N-methyltransferase (NNMT) is an enzyme that converts the NAM (nicotinamide) to its methylated form, N1-methylnicotinamide (MNAM). Higher levels of MNAM have been reported in cases with coronary artery disease (CAD). Further, MNAM increases endothelial prostacyclin (PGI2) and nitric oxide (NO) and thereby causes vasorelaxation. The vasoprotective, anti-inflammatory and anti-thrombotic roles of MNAM have been well documented; however, the exact underlying mechanisms remain to be clarified. Due to potential role of MNAM in the formation of lipid droplets (LDs), it might exert its function in coordination with lipids, and their targets. In this study, we summarized the roles of MNAM in cardiovascular system and highlighted its possible mode of actions.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  N-methyltransferase; N1-methylnicotinamide; atherosclerosis; coronary artery disease; lipid droplets

Mesh:

Substances:

Year:  2018        PMID: 29741779     DOI: 10.1002/jcp.26636

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  8 in total

1.  Mutant Nmnat1 leads to a retina-specific decrease of NAD+ accompanied by increased poly(ADP-ribose) in a mouse model of NMNAT1-associated retinal degeneration.

Authors:  Scott H Greenwald; Emily E Brown; Michael J Scandura; Erin Hennessey; Raymond Farmer; Jianhai Du; Yekai Wang; Eric A Pierce
Journal:  Hum Mol Genet       Date:  2021-05-17       Impact factor: 6.150

2.  Nicotinamide's Ups and Downs: Consequences for Fertility, Development, Longevity and Diseases of Poverty and Affluence.

Authors:  Adrian C Williams; Lisa J Hill
Journal:  Int J Tryptophan Res       Date:  2018-10-09

3.  Metabolomic Fingerprinting of Infants Undergoing Cardiopulmonary Bypass: Changes in Metabolic Pathways and Association With Mortality and Cardiac Intensive Care Unit Length of Stay.

Authors:  Jesse A Davidson; Zachary Pfeifer; Benjamin Frank; Suhong Tong; Tracy T Urban; Paul A Wischmeyer; Peter Mourani; Bruce Landeck; Uwe Christians; Jelena Klawitter
Journal:  J Am Heart Assoc       Date:  2018-12-18       Impact factor: 5.501

4.  Association of Coronary Artery Disease and Metabolic Syndrome: Usefulness of Serum Metabolomics Approach.

Authors:  Ziwei Jing; Liwei Liu; Yingying Shi; Qiuzheng Du; Dingding Zhang; Lihua Zuo; Shuzhang Du; Zhi Sun; Xiaojian Zhang
Journal:  Front Endocrinol (Lausanne)       Date:  2021-09-24       Impact factor: 5.555

Review 5.  Nutraceutical and Dietary Strategies for Up-Regulating Macroautophagy.

Authors:  Mark F McCarty
Journal:  Int J Mol Sci       Date:  2022-02-12       Impact factor: 5.923

6.  Remote solid cancers rewire hepatic nitrogen metabolism via host nicotinamide-N-methyltransferase.

Authors:  Rin Mizuno; Hiroaki Hojo; Masatomo Takahashi; Soshiro Kashio; Sora Enya; Motonao Nakao; Riyo Konishi; Mayuko Yoda; Ayano Harata; Junzo Hamanishi; Hiroshi Kawamoto; Masaki Mandai; Yutaka Suzuki; Masayuki Miura; Takeshi Bamba; Yoshihiro Izumi; Shinpei Kawaoka
Journal:  Nat Commun       Date:  2022-06-15       Impact factor: 17.694

7.  A Diet Supplemented with Polyphenols, Prebiotics and Omega-3 Fatty Acids Modulates the Intestinal Microbiota and Improves the Profile of Metabolites Linked with Anxiety in Dogs.

Authors:  Eden Ephraim; Jeffrey A Brockman; Dennis E Jewell
Journal:  Biology (Basel)       Date:  2022-06-28

8.  N1-Methylnicotinamide Improves Hepatic Insulin Sensitivity via Activation of SIRT1 and Inhibition of FOXO1 Acetylation.

Authors:  Jingfan Zhang; Yu Chen; Cong Liu; Ling Li; Ping Li
Journal:  J Diabetes Res       Date:  2020-03-23       Impact factor: 4.011

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.